secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0000950170-24-132302
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC
--------------------------------------------------------------------------------

- 100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.
- 75% maintained PSA50 and 50% maintained PSA90 at ≥12 weeks.
- 50% ORR (4/8 RECIST-evaluable patients) with confirmed/unconfirmed partial responses.
- CRS and TRAEs primarily cycle 1, grade 1-2; MTD not yet reached.
- Two once-weekly step dose regimens identified for Phase 1b in pre-PLUVICTO 2L/3L patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024132302/0000950170-24-132302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024132302/janx-20241202.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-132302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer